• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21959 Records] Selected Records [0 Hits] [Clear]
Year Source Title
1997     Scottish Health Purchasing Information Centre (SHPIC) Dexfenfluramine in obesity [Briefing note]
2020     Scottish Health Technologies Group (SHTG) The Scottish asynchronous digital dermatology appointment service (DDAS)
2015     Scottish Health Technologies Group (SHTG) Antimicrobial wound dressings (AWDs) for chronic wounds: Health technology assessment report 13
2021     Scottish Health Technologies Group (SHTG) Detection of paroxysmal atrial fibrillation in patients with newly diagnosed ischaemic stroke
2013     Scottish Health Technologies Group (SHTG) Is patient self-monitoring (including self-testing and self-management) of oral anticoagulation therapy safe, efficacious and cost-effective?
2022     Scottish Health Technologies Group (SHTG) Closed loop systems and the artificial pancreas for type I diabetes mellitus (T1DM)
2021     Scottish Health Technologies Group (SHTG) Minuteful Kidney for home testing of albumin-to-creatine ratio (ACR)
2021     Scottish Health Technologies Group (SHTG) Chest wall bracing for children and young people with pectus carinatum
2022     Scottish Health Technologies Group (SHTG) vCreate Neuro for the diagnosis and treatment of adults and children with epilepsy and other neurological disorders
2023     Scottish Health Technologies Group (SHTG) Tumour profiling tests to guide chemotherapy decisions in early breast cancer
2020     Scottish Health Technologies Group (SHTG) The SARUS (safer - airway - resuscitation) - CPR hood to protect first responders from biohazards
2023     Scottish Health Technologies Group (SHTG) Community based respiratory care services for patients with chronic respiratory conditions
2020     Scottish Health Technologies Group (SHTG) Dxcover brain cancer liquid biopsy test for early brain cancer detection in primary care
2023     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2023     Scottish Health Technologies Group (SHTG) The clinical effectiveness and cost effectiveness of a digital type 2 diabetes remission programme
2014     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults at high surgical risk
2023     Scottish Health Technologies Group (SHTG) The cost-effectiveness of the Scottish Hip Fracture Audit
2014     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults who are not eligible for surgery
2023     Scottish Health Technologies Group (SHTG) Outpatient parenteral antimicrobial therapy (OPAT) cost calculator
2023     Scottish Health Technologies Group (SHTG) Living donor transplantation
2023     Scottish Health Technologies Group (SHTG) Placental growth factor (PlGF)-based testing to help diagnose suspected preterm pre-eclampsia
2023     Scottish Health Technologies Group (SHTG) An assessment of the Feeling Good app
2014     Scottish Health Technologies Group (SHTG) Are homeopathic remedies clinically and cost effective in the treatment of migraine and osteoarthritis?
2023     Scottish Health Technologies Group (SHTG) Consideration of selective internal radiation therapies (SIRT) for treating primary hepatocellular carcinoma (liver cancer)
2023     Scottish Health Technologies Group (SHTG) Store-and-forward teledermatology for triage of primary care referrals
2023     Scottish Health Technologies Group (SHTG) Orthotic bracing for the treatment of idiopathic scoliosis in children and young people (less than 18 years)
2022     Scottish Health Technologies Group (SHTG) The Psychology Adding Value – Epilepsy Screening (PAVES) and early intervention for children and young people with epilepsy at risk of mental health problems
2022     Scottish Health Technologies Group (SHTG) A national radiology information system (RIS) for Scotland: perceived benefits and constraints to implementation
2011     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults
2023     Scottish Health Technologies Group (SHTG) Bacteriophage therapy for patients with difficult to treat bacterial infections
2020     Scottish Health Technologies Group (SHTG) Second-generation colon capsule endoscopy (CCE-2) for the detection of colorectal polyps – SHTG Recommendation
2020     Scottish Health Technologies Group (SHTG) Pre-treatment DPYD genetic testing for patients who are prescribed chemotherapy involving fluoropyrimidines – SHTG Assessment
2020     Scottish Health Technologies Group (SHTG) Continuous glucose monitoring in pregnant women with type 1 diabetes – SHTG Adaptation
2020     Scottish Health Technologies Group (SHTG) Endobronchial valves for lung volume reduction in patients with severe or very severe emphysema - SHTG Recommendation
2024     Scottish Health Technologies Group (SHTG) Lung cancer AI
2024     Scottish Health Technologies Group (SHTG) Colon capsule endoscopy
2021     Scottish Health Technologies Group (SHTG) NHSScotland COPD Support Service: remote and self-management of high-risk patients with COPD using a web app and machine learning predictive modelling
2011     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of the ThinPrep imager® (HologicTM, Inc) for assisted cervical cytology compared with manual reading of liquid based cytology slides?
2011     Scottish Health Technologies Group (SHTG) The clinical and cost effectiveness of the use of brachytherapy to treat breast cancer
2011     Scottish Health Technologies Group (SHTG) What is the evidence base for the use of orthopaedic spinal surgery for mechanical low back pain or degenerative spondylolisthesis?
2011     Scottish Health Technologies Group (SHTG) The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer
2011     Scottish Health Technologies Group (SHTG) Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults. This evidence note updates evidence note 33 published in March 2011
2011     Scottish Health Technologies Group (SHTG) The clinical and cost effectiveness of long-term ventricular assist devices (VADs) as a bridge-to-transplant in adults
2011     Scottish Health Technologies Group (SHTG) Is radiofrequency ablation treatment a clinically and cost effective treatment to be offered to people with renal cancer in NHSScotland?
2012     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of human papillomavirus (HPV) testing, followed by liquid-based cytology triage of positive results, in primary screening for cervical cancer?
2012     Scottish Health Technologies Group (SHTG) High-risk human papillomavirus (HPV) testing as triage for women with mild or borderline cytology abnormalities
2012     Scottish Health Technologies Group (SHTG) Is radiofrequency ablation (RFA) treatment a suitable clinically and cost-effective treatment to be offered to patients with hepatocellular cancer in NHSScotland?
2012     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of microprocessor-controlled artificial knees compared with non-microprocessor-controlled alternatives?
2012     Scottish Health Technologies Group (SHTG) Radiofrequency ablation for Barrett's oesophagus with high grade dysplasia
2012     Scottish Health Technologies Group (SHTG) The use of functional electrical stimulation (FES) in adults with dropped foot. This evidence note updates evidence note 25 published in October 2008
2012     Scottish Health Technologies Group (SHTG) Safety and risk associated with free standing midwife led maternity units. This evidence note updates evidence note 18 published in August 2007
2013     Scottish Health Technologies Group (SHTG) Does the addition of positron emission tomography/computed tomography (PET/CT) to the routine investigation and assessment of patients with melanoma yield clinical and economic benefits?
2013     Scottish Health Technologies Group (SHTG) Open, laparoscopic and robot-assisted laparoscopic radical prostatectomy for localised prostate cancer.
2012     Scottish Health Technologies Group (SHTG) What implications does the organisation of vascular services have for rates of amputation?
2012     Scottish Health Technologies Group (SHTG) What is the published evidence of an association between hospital volume and outcome in elective carotid endarterectomy surgery?
2012     Scottish Health Technologies Group (SHTG) Is there a difference in operative mortality between endovascular aneurysm repair and open surgery in elective abdominal aortic aneurysm?
2012     Scottish Health Technologies Group (SHTG) What is the published evidence of an association between hospital volume and operative mortality for surgical repair (open and endovascular) of unruptured and ruptured abdominal aortic aneurysms?
2012     Scottish Health Technologies Group (SHTG) In patients with severe medically refractory gastroparesis (such as those requiring nutritional support), how effective and cost effective is gastric electrical stimulation (EnterraTM device) in reducing symptoms, reducing requirement for nutritional support or hospitalisation and improving quality of life, when compared with medical or alternative surgical management?
2012     Scottish Health Technologies Group (SHTG) What is the relative clinical effectiveness, cost effectiveness and safety of different bariatric surgery techniques (gastric bypass, gastric banding and sleeve gastrectomy)?
2012     Scottish Health Technologies Group (SHTG) In radiotherapy for cancer, what are the patient safety benefits and resource implications of the various in vivo methods of dosimetry to check received radiation dose, compared with pretreatment verification only?
2012     Scottish Health Technologies Group (SHTG) Is it clinically and cost effective to perform second-eye cataract surgery in the absence of other ocular co-morbidities in patients who have already had first-eye surgery?
2012     Scottish Health Technologies Group (SHTG) What is the impact of using thresholds (both for referral and surgery) for first-eye cataract surgery on the delivery of the cataract service and the resources associated with it?
2012     Scottish Health Technologies Group (SHTG) The clinical and cost-effectiveness of radiofrequency ablation for lung cancer
2012     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of temporal artery thermometers compared with infrared in-ear thermometers for temperature measurement in routine clinical practice?
2013     Scottish Health Technologies Group (SHTG) Are silver dressings clinically effective and cost effective for the healing of infected wounds and the prevention of wound infection relative to other types of dressing?
2013     Scottish Health Technologies Group (SHTG) Does the addition of positron emission tomography/computed tomography (PET/CT) to the routine investigation and assessment of patients with sarcoidosis yield clinical and economic benefits?
2013     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of dynamic elastomeric fabric orthoses (DEFOs) for cerebral palsy?
2013     Scottish Health Technologies Group (SHTG) Can wrist splints or steroid injections reduce the need for decompression surgery in carpal tunnel syndrome?
2013     Scottish Health Technologies Group (SHTG) What is the sensitivity and specificity of PET/CT compared with other diagnostic imaging modalities in determining the cause of pyrexia of unknown origin (PUO)? What is the clinical and cost effectiveness of PET/CT as a first-line investigation in patients with PUO?
2013     Scottish Health Technologies Group (SHTG) What is the clinical effectiveness, cost effectiveness and implications for safety of assessing anti-tumour necrosis factor (TNF)α drug levels and antibodies in children with moderate to severe inflammatory bowel disease compared with existing clinical strategies in use in NHS Scotland?
2013     Scottish Health Technologies Group (SHTG) PET/CT for the inversitgation of paraneoplastic syndromes (PNS)
2013     Scottish Health Technologies Group (SHTG) Is patient self-monitoring (including self-testing and self-management) of oral anticoagulation therapy safe, efficacious, and cost effective? (update of EN 27)
2014     Scottish Health Technologies Group (SHTG) What is the clinical and cost effectiveness of treatment with renal denervation for patients with resistant hypertension?
2013     Scottish Health Technologies Group (SHTG) What is the evidence for the clinical and cost effectiveness of major trauma centres as the core component of a trauma service, compared with standard care for adults with major trauma?
2013     Scottish Health Technologies Group (SHTG) Is cone beam computed tomography (CBCT) clinically effective, cost-effective and safe compared with standard extraoral and intraoral radiography in the diagnosis of hard tissue pathology in routine dental practice?
2013     Scottish Health Technologies Group (SHTG) What approaches have been taken and efforts made to ensure public involvement in decision making relating to potential disinvestment in healthcare interventions and technologies?
2014     Scottish Health Technologies Group (SHTG) In the context of hypothyroidism, what is the evidence for the effectiveness of diagnostic tests and thyroid hormone replacement therapies?
2020     Scottish Health Technologies Group (SHTG) HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography
2023     Scottish Health Technologies Group (SHTG) Technology enabled theatre scheduling tools
2024     Scottish Health Technologies Group (SHTG) Green theatres
2021     Scottish Health Technologies Group (SHTG) Elective surgery using mesh to repair primary or incisional hernias in adults
2021     Scottish Health Technologies Group (SHTG) A Unique Device Identifier (UDI) system for recording, identifying and recalling medical devices
2015     Scottish Health Technologies Group (SHTG) Magnetic resonance guided focused ultrasound surgery (MRgFUS) for the treatment of uterine fibroids
2023     Scottish Health Technologies Group (SHTG) Priorities for the north imaging alliance
2023     Scottish Health Technologies Group (SHTG) The cost-effectiveness of the Scottish Hip Fracture Audit
2023     Scottish Health Technologies Group (SHTG) Capsule sponge technologies for the detection of Barrett’s oesophagus and early stage oesophageal cancer
2023     Scottish Health Technologies Group (SHTG) Technology-enabled theatre scheduling systems
2023     Scottish Health Technologies Group (SHTG) Digital prevention programme for people at risk of type 2 diabetes
2024     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2024     Scottish Health Technologies Group (SHTG) Volatile capture technologies
2024     Scottish Health Technologies Group (SHTG) Digital cancer prehabilitation
2024     Scottish Health Technologies Group (SHTG) Clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack (TIA)
2021     Scottish Medicines Consortium (SMC) Fostamatinib treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments
2021     Scottish Medicines Consortium (SMC) Entrectinib for the treatment of patients with ROS1-positive, advanced non-small-cell lung cancer (NSCLC) not previously treated with ROS-1 inhibitors
2021     Scottish Medicines Consortium (SMC) Afamelanotide (Scenesse) for prevention of photoxicity in adult patients with erythropoietic protoporphyria (EPP)
2021     Scottish Medicines Consortium (SMC) Upadacitinib for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)
2021     Scottish Medicines Consortium (SMC) Ravulizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity; in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months
2021     Scottish Medicines Consortium (SMC) Ozanimod for adult patients with relapsing remitting multiple sclerosis
2021     Scottish Medicines Consortium (SMC) Entrectinib as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion: who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity; and who have not received a prior NTRK inhibitor; who have no satisfactory treatment options
2021     Scottish Medicines Consortium (SMC) Onasemnogene abeparvovec treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene